{
    "clinical_study": {
        "@rank": "151579", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.   Compare the safety of sodium dichloroacetate (DCA) vs placebo in children with\n      congenital lactic acidosis.\n\n      II.  Determine the quality of life of these patients.\n\n      III. Determine the pharmacokinetics and metabolic fate of DCA over the course of drug\n      administration in these patients."
        }, 
        "brief_title": "Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis", 
        "condition": "Lactic Acidosis", 
        "condition_browse": {
            "mesh_term": [
                "Acidosis", 
                "Acidosis, Lactic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, crossover study.  Patients are\n      stratified according to age (3 months to 2 years vs over 2 to 18 years).\n\n      All patients receive at least 12 months of sodium dichloroacetate (DCA) during a 2 year\n      period of double blind, crossover evaluation of DCA and placebo by mouth.\n\n      Quality of life is assessed before treatment and periodically during treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of congenital lactic acidosis (CLA) meeting the following criteria: Three basal\n        venous lactates at least 2.5 mM, arterial lactates at least 2.0 mM, or CSF lactates at\n        least 2.5 mM OR any combination of these, obtained over at least 1 month and within 6\n        months OR Increase in blood lactate at least 1.0 mM over basal following a carbohydrate\n        meal challenge\n\n        AND\n\n        Enzymatic or molecular genetic proof of a defect of pyruvate dehydrogenase complex, one or\n        more respiratory chain enzymes, or a Krebs cycle enzyme OR Over production of C14-lactate\n        from C14-glucose by cultured skin fibroblasts\n\n        AND\n\n        Ability to withstand an 8 hour (if 2 years and under) or 12 hour (if over 2 years) fast\n        without developing hypoglycemia (blood glucose less than 50 mg/dL)\n\n        No secondary lactic acidosis due to impaired oxygenation or circulation\n\n        No hyperlactatemia associated with proven biotinidase deficiency (biotin responsive CLA)\n        or with enzyme deficiencies of gluconeogenesis\n\n        No primary, defined organic acidurias other than lactic acidosis, for which effective\n        therapy is available (e.g., propionic aciduria)\n\n        No primary disorders of amino acid metabolism or fatty acid oxidation\n\n        No malabsorption syndromes associated with D-lactic acidosis\n\n        --Prior/Concurrent Therapy--\n\n        No chronic dialysis\n\n        --Patient Characteristics--\n\n        Hepatic: No primary hepatic disease unrelated to CLA\n\n        Renal: Creatinine less than 1.2 mg/dL OR Creatinine clearance at least 60 mL/min\n\n        Other: No concurrent infection or fever"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": "45", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004490", 
            "org_study_id": "199/14271", 
            "secondary_id": [
                "UF-G-FDR001500", 
                "UF-G-183-92"
            ]
        }, 
        "intervention": {
            "intervention_name": "sodium dichloroacetate", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "disease-related problem/condition", 
            "inborn errors of metabolism", 
            "lactic acidosis", 
            "quality of life", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Peter W. Stacpoole", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004490"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 1998", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {}
}